• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Treatment strategies for dystonia.治疗肌张力障碍的策略。
Expert Opin Pharmacother. 2010 Jan;11(1):5-15. doi: 10.1517/14656560903426171.
2
Treatment of dystonia.肌张力障碍的治疗。
Lancet Neurol. 2006 Oct;5(10):864-72. doi: 10.1016/S1474-4422(06)70574-9.
3
Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System.肉毒毒素治疗口颌面部肌张力障碍和口腔颌面部运动障碍。
Toxins (Basel). 2022 Apr 14;14(4):282. doi: 10.3390/toxins14040282.
4
Treatment of dystonia.肌张力障碍的治疗。
Expert Rev Neurother. 2006 Jun;6(6):863-86. doi: 10.1586/14737175.6.6.863.
5
Therapeutic challenges in dystonia.肌张力障碍的治疗挑战。
Neurol Clin. 2010 Nov;28(4):927-40. doi: 10.1016/j.ncl.2010.03.020. Epub 2010 Jul 14.
6
Response to EFNS guidelines on treatment of Dystonia article.对欧洲神经科学联合会(EFNS)关于肌张力障碍治疗指南文章的回应。
Eur J Neurol. 2011 Jun;18(6):e60-1; author reply e62. doi: 10.1111/j.1468-1331.2010.03343.x. Epub 2011 Feb 14.
7
Dystonia: medical therapy and botulinum toxin.肌张力障碍:药物治疗与肉毒杆菌毒素
Adv Neurol. 2004;94:275-86.
8
The Dystonias.《肌张力障碍》
Continuum (Minneap Minn). 2022 Oct 1;28(5):1435-1475. doi: 10.1212/CON.0000000000001159.
9
Botulinum toxin treatment of axial and cervical dystonia.肉毒杆菌毒素治疗轴性和颈部肌张力障碍。
Disabil Rehabil. 2007 Dec 15;29(23):1769-77. doi: 10.1080/01421590701568262.
10
Dystonia: genetics and treatment update.肌张力障碍:遗传学与治疗进展
Neurologist. 2006 Mar;12(2):74-85. doi: 10.1097/01.nrl.0000195831.46000.2d.

引用本文的文献

1
Post-thalamotomy Changes Mimicking Cavernous Malformations on MRI: A Case Report of a Historical Surgical Treatment.丘脑切开术后MRI表现酷似海绵状血管畸形:一例历史手术治疗病例报告
Cureus. 2025 Apr 16;17(4):e82380. doi: 10.7759/cureus.82380. eCollection 2025 Apr.
2
Clinical Features of Families with a Novel Pathogenic Mutation in Sepiapterin Reductase.蝶呤还原酶新致病性突变家族的临床特征
Int J Mol Sci. 2025 Mar 27;26(7):3056. doi: 10.3390/ijms26073056.
3
Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure.肉毒杆菌神经毒素治疗暴露分析颈部肌张力障碍患者吞咽困难和合并症的发生率
Toxins (Basel). 2025 Mar 19;17(3):148. doi: 10.3390/toxins17030148.
4
Review: Botulinum Toxin for Treatment of Focal Limb Dystonia.综述:肉毒杆菌毒素治疗局灶性肢体肌张力障碍
Toxins (Basel). 2025 Mar 4;17(3):122. doi: 10.3390/toxins17030122.
5
Symptomatic Treatment of Extrapyramidal Hyperkinetic Movement Disorders.锥体外系运动障碍的对症治疗。
Curr Neuropharmacol. 2024;22(14):2284-2297. doi: 10.2174/1570159X22666240517161444.
6
Neurosurgical and pharmacological management of dystonia.肌张力障碍的神经外科及药物治疗
World J Psychiatry. 2024 May 19;14(5):624-634. doi: 10.5498/wjp.v14.i5.624.
7
Case report: Intrathecal baclofen therapy improved gait pattern in a stroke patient with spastic dystonia.病例报告:鞘内注射巴氯芬疗法改善了一名患有痉挛性肌张力障碍的中风患者的步态模式。
Front Neurol. 2024 Feb 14;15:1330811. doi: 10.3389/fneur.2024.1330811. eCollection 2024.
8
Deep brain stimulation in pediatric dystonia: calls for therapeutic realism over nihilism.儿童期肌张力障碍的深部脑刺激:呼吁超越虚无主义的治疗现实主义。
Childs Nerv Syst. 2024 Mar;40(3):881-894. doi: 10.1007/s00381-023-06182-x. Epub 2023 Oct 25.
9
Two-Generation Epsilon-Sarcoglycan Gene (SGCE) Mutation-Associated Myoclonus-Dystonia (DYT-SGCE) Misdiagnosed as Tourette's Syndrome: A Case Series.两代ε-肌聚糖基因(SGCE)突变相关的肌阵挛性肌张力障碍(DYT-SGCE)被误诊为抽动秽语综合征:病例系列
Cureus. 2023 Sep 15;15(9):e45289. doi: 10.7759/cureus.45289. eCollection 2023 Sep.
10
Development of a Selective and High Affinity Radioligand, [H]VU6013720, for the M Muscarinic Receptor.开发一种选择性和高亲和力的放射性配体 [H]VU6013720,用于 M 毒蕈碱受体。
Mol Pharmacol. 2023 Nov;104(5):195-202. doi: 10.1124/molpharm.122.000643. Epub 2023 Aug 18.

本文引用的文献

1
Treatment of focal dystonias with botulinum neurotoxin.肉毒杆菌神经毒素治疗局灶性肌张力障碍
Toxicon. 2009 Oct;54(5):628-33. doi: 10.1016/j.toxicon.2008.12.008. Epub 2008 Dec 13.
2
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.评估:肉毒杆菌神经毒素用于治疗运动障碍(循证综述)[已停用]:美国神经病学学会治疗与技术评估小组委员会报告
Neurology. 2008 May 6;70(19):1699-706. doi: 10.1212/01.wnl.0000311389.26145.95.
3
Treatment of dystonia with deep brain stimulation.深部脑刺激治疗肌张力障碍
Neurotherapeutics. 2008 Apr;5(2):320-30. doi: 10.1016/j.nurt.2008.01.002.
4
Experimental therapeutics for dystonia.肌张力障碍的实验性治疗方法。
Neurotherapeutics. 2008 Apr;5(2):198-209. doi: 10.1016/j.nurt.2008.01.001.
5
The Canadian multicentre study of deep brain stimulation for cervical dystonia.加拿大深部脑刺激治疗颈部肌张力障碍多中心研究。
Brain. 2007 Nov;130(Pt 11):2879-86. doi: 10.1093/brain/awm229. Epub 2007 Sep 28.
6
Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome).苍白球深部脑刺激治疗颅颈肌张力障碍(梅杰综合征)患者。
Mov Disord. 2007 Oct 15;22(13):1885-91. doi: 10.1002/mds.21580.
7
Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study.原发性全身性肌张力障碍的双侧苍白球深部脑刺激:一项前瞻性3年随访研究。
Lancet Neurol. 2007 Mar;6(3):223-9. doi: 10.1016/S1474-4422(07)70035-2.
8
Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia.双侧苍白球深部脑刺激治疗原发性颈部肌张力障碍的长期疗效
Neurology. 2007 Feb 6;68(6):457-9. doi: 10.1212/01.wnl.0000252932.71306.89.
9
Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia.双侧苍白球深部脑刺激治疗迟发性运动障碍。
Arch Gen Psychiatry. 2007 Feb;64(2):170-6. doi: 10.1001/archpsyc.64.2.170.
10
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.丁苯那嗪治疗运动亢进性运动障碍的长期耐受性
Mov Disord. 2007 Jan 15;22(2):193-7. doi: 10.1002/mds.21222.

治疗肌张力障碍的策略。

Treatment strategies for dystonia.

机构信息

Emory University, Department of Neurology, 1841 Clifton Road NE, Room 329, Atlanta, GA 30029, USA.

出版信息

Expert Opin Pharmacother. 2010 Jan;11(1):5-15. doi: 10.1517/14656560903426171.

DOI:10.1517/14656560903426171
PMID:20001425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3495548/
Abstract

IMPORTANCE OF THE FIELD

Dystonia is a neurological syndrome characterized by involuntary twisting movements and unnatural postures. It has many different manifestations and causes, and many different treatment options are available. These options include physical and occupational therapy, oral medications, intramuscular injection of botulinum toxins, and neurosurgical interventions.

AREAS COVERED IN THIS REVIEW

In this review, we first summarize the treatment options available, then we provide suggestions from our own experience for how these can be applied in different types of dystonia. In preparing this review article, an extensive literature search was undertaken using PubMed. Only selected references from 1970 to 2008 are cited.

WHAT THE READER WILL GAIN

This review is intended to provide the clinician with a practical guide to the treatment of dystonia.

TAKE HOME MESSAGE

Treatment of dystonia begins with proper diagnosis and classification, followed by an appropriate search for underlying etiology, and an assessment of the functional impairment associated with the dystonia. The therapeutic approach, which is usually limited to symptomatic therapy, must then be tailored to the individual needs of the patient.

摘要

重要性领域

肌张力障碍是一种以不自主扭曲运动和异常姿势为特征的神经系统综合征。它有许多不同的表现形式和原因,也有许多不同的治疗选择。这些选择包括物理和职业治疗、口服药物、肌肉内注射肉毒毒素和神经外科干预。

本篇综述涵盖的内容

在这篇综述中,我们首先总结了现有的治疗选择,然后根据我们的经验,就如何将这些选择应用于不同类型的肌张力障碍提出了建议。在准备这篇综述文章时,我们使用 PubMed 进行了广泛的文献检索。只引用了 1970 年至 2008 年的精选参考文献。

读者将获得什么

这篇综述旨在为临床医生提供肌张力障碍治疗的实用指南。

重要信息

肌张力障碍的治疗始于正确的诊断和分类,然后寻找潜在病因,并评估与肌张力障碍相关的功能障碍。治疗方法通常仅限于对症治疗,然后必须根据患者的个体需求进行调整。